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h Abstract
Objective. It is well known that receipt of an initial ab-
normal cervical cytology test can trigger considerable anxiety
among women. Less is known about the impact of follow-
up by repeat cytology tests. We quantified prevalence, and
identified predictors, of distress after repeat cytologic testing
in women with a single low-grade test.
Methods. Within the framework of the TOMBOLA ran-
domized controlled trial of alternative managements,
844 women aged 20 to 59 years with a single routine cytol-
ogy test showing borderline nuclear abnormalities (BNA;
broadly equivalent to atypical squamous cells of undeter-
mined significance) were assigned to follow-up by repeat
cytology in primary care (the first test was due 6 months
after the initial BNA result). Women completed socio-
demographic and psychosocial questionnaires at recruit-
ment and the Impact of Event Scale (IES) 6 weeks after their
first follow-up cytology test. Factors associated with signif-
icant psychologic distress (IES Q 9) were identified using lo-
gistic regression.
Results. The response rate was 74% (n = 621/844). Of
all the respondents, 39% scored in the range for signif-
icant distress. Distress varied by follow-up cytology result:
negative, 36%; BNA or mild dyskaryosis, 42%; other (in-
cluding high grade and inadequate), 55%. After adjust-
ing for the cytology result, risk of distress was significantly
raised inwomenwhohad significant anxiety at recruitment,
reported experiencing pain after the follow-up cytology,
had children, or were dissatisfied with support they had
received after their initial BNA test.
Conclusions. Substantial proportions of women expe-
rience surveillance-related psychologic distress after a follow-
up cytology test, even when the result is negative. This is
an important, albeit unintended, consequence of cervical
screening. Strategies to alleviate this distress merit attention.
h
Key Words: atypical squamous cells of undetermined sig-
nificance, cervical screening, follow-up, distress
In countries with population-based screening programsbetween 4% and 12% of all adequate cytology tests show
low-grade abnormalities [1Y3], most of which are classi-
fied as atypical squamous cells of uncertain significance
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(ASC-US) or equivalent. Guidelines in many jurisdictions
state that repeat cytologic testing is an acceptable man-
agement option for women with a single ASC-US test
result [4Y7].
It is well established that a routine cervical cytology
test that shows abnormalities often causes women con-
siderable anxiety [8, 9]. However, relatively little is known
about the psychologic impact of follow-up by repeat cy-
tologic tests. A small number of studies have investigated
psychologic consequences of repeat cytology testing, mainly
in the context of comparing different management ap-
proaches. Two of these studies did not include women
with ASC-US (or equivalent) routine cytology tests [10, 11]
and two others included mixed groups of women with
cytology showing ASC-US and low-grade squamous intra-
epithelial lesions (LSILs), or borderline nuclear abnormali-
ties (BNAs) and mild dyskaryosis [12, 13]. One study from
Australia was limited to women who had had a routine
BNA cytology test; in that study, the mean distress score
estimated from 3 measurements taken for 12 months
among 71 women who were managed by repeat cytology
was double that for women with a negative routine cy-
tology test [14]. Although these findings indicate that
women with a BNA result who require repeat cytology
tests are at an increased risk of distress, they do not dis-
tinguish between the effects of the initial (routine) test
and the follow-up test.
The aims of this study were to quantify the prevalence
of distress after repeat cytologic testing in women with a
single BNA routine cytology test, to determine how this
varies according to the result of the repeat test, and to
identify other predictors of distress.
METHODS
Participants
This study was nested within the cytologic surveillance
arm of the TOMBOLA randomized controlled trial, full
details of which are described elsewhere [15, 16]. Briefly,
women were eligible if they were aged 20 to 59 years and
were residents of the Grampian, Tayside, and Notting-
ham areas of the United Kingdom and had had a recent
routine low-grade cervical cytology result (mild dyskaryosis
or BNA; broadly equivalent to LSIL and ASC-US) [17]
taken within the NHS Cervical Screening Programmes
(CSPs). Women who agreed to take part in TOMBOLA
were randomized to either repeat cytology tests (cyto-
logic surveillance) or a colposcopy examination.
Women who were randomized to cytologic surveil-
lance were recommended to have 6-monthly cytology
tests in primary care (i.e., at their general practitioner or
family planning clinic), with the first surveillance test due
6 months after the cytology test that made them eligible
for TOMBOLA. About 1 month before the first surveil-
lance test being due, a ‘‘trigger’’ letter was sent to both the
woman and her GP reminding them that the test was due.
Women who attended for that test, and for whom the test
result was negative or low-grade, remained on 6-monthly
surveillance cytology testing; those who had an inade-
quate result were recommended to have another test
within 3 months; and those with a high-grade result were
referred to colposcopy in the local NHS clinic.
Women included in the current study had a BNA re-
cruitment test result, no abnormal cytology in the previ-
ous 3 years, and attended for their first surveillance
cytology test after the date on which the administration
of psychologic questionnaires began (December 2001).
Ethical approval was obtained from the joint Re-
search Ethics Research Committee of NHS Grampian
and the University of Aberdeen, the Tayside Committee
on Medical Research Ethics and the Nottingham Re-
search Ethics Committee.
Assessment of Outcome
The primary outcome was cytologic surveillance-related
distress, assessed by the Impact of Event Scale (IES), a
validated and reliable 15-item measure of subjective psy-
chologic distress associated with a specific stressful or
traumatic event [18, 19]. Respondents assess how often
they have experienced each of the 15 phenomena in the
past 7 days (e.g., ‘‘I thought about it [the event] when
I didn’t mean to’’). The event, in this instance, was de-
fined as the first surveillance cytology test.
Women were sent the IES approximately 6 weeks after
their surveillance cytology test. Six weeks was chosen to
ensure that, by the time women received the question-
naire, they would have received their cytology result.
Those who did not respond to the questionnaire were
sent a maximum of 2 reminders, 2 weeks apart.
Assessment of Potential Explanatory Variables
Information on potential explanatory variables was ob-
tained from sociodemographic, lifestyle, and psychologic
questionnaires administered at trial recruitment (on aver-
age, 8 weeks after they received the result of their routine
cytology test) and from a physical after-effects question-
naire completed at the same time as the IES. The psycho-
logic questionnaires included the Hospital Anxiety and
Depression Scale (HADS) [20], the Multidimensional







Health Locus of Control Scale (MHLCS), which measures
three dimensions of health locus of control (internal,
chance, and powerful others) [21], and the process out-
come specific measure (POSM), which asks about spe-
cific issues that are of concern to women undergoing
follow-up for abnormal cytology results [22]. The physi-
cal after-effects questionnaire asked about pain, bleeding,
and discharge experienced after the surveillance cytology
test [23]. For analysis purposes, women were also clas-
sified by the time between the BNA cytology that made
them eligible for the trial and their first surveillance cy-
tology test (e6, 7Y9, 10Y12, and Q13 mo).
Statistical Analysis
Women who completed all 15 IES items were included in
the analysis. IES scores were not normally distributed,
therefore women were classified dichotomously as ‘‘cases’’
or ‘‘noncases,’’ using a total IES score of 9 or higher to
define cytologic surveillance-related psychologic distress
[24, 25]. Using recognized cutoffs, ‘‘cases’’ were also
classified as having mild (score = 9Y25), moderate (score =
26Y43), or severe (score Q44) distress. Logistic regression
models were used to identify factors associated with dis-
tress of any severity. There were 2 stages of model fitting.
In the first stage, we built a multivariate model from
among the sociodemographic, lifestyle, HADS, MHLCS,
physical after-effects, and time-to-surveillance test variables.
Because we were specifically interested in associations be-
tween the result of the follow-up test and distress, cytology
result was forced into the model (with the result classified
as negative, low-grade [BNA/mild dyskaryosis], or other
[moderate or severe dyskaryosis/inadequate/?glandular]).
We then assessed variables relating to anxiety or de-
pression at recruitment; then physical after-effects,
sociodemographic, and lifestyle variables; the MHLCS
dimensions; and finally, time to the surveillance cytol-
ogy test. In these analyses, women were classified into
3 groups for anxiety and depression using standard cutoffs
(noncase, subscale score G8; possible case, score = 8Y10;
probably case, score Q11); scores for the 3 MHLCS di-
mensions were treated as continuous and responses to the
questions about the 3 physical after-effects were coded
dichotomously according to whether a reported having
experienced each after-effect. Variables were included in
the final models only if they were significant on a likeli-
hood ratio test (LRT, p e .05) comparing the (adjusted)
model with, and the model without, the relevant vari-
able. The multivariate model from this stage of the anal-
ysis had adequate fit as assessed by the Hosmer and
Lemeshow test [26]. In the second stage of model fitting,
we investigated whether the variables from the POSM
were associated with distress, after adjusting for other
important predictors (i.e., the variables from the first stage
of model fitting). For this analysis, women’s responses to
the POSM questions were classified into 2 groups (yes/no).
This final model was used to produce adjusted percentages
of women who were distressed.
To investigate the possibility that time since last pro-
cedure influenced distress, a sensitivity analysis was con-
ducted in which prevalence of distress was computed
according to whether women had responded to the




The study included 844 women, of whom 621 completed
all 15 items on the IES (response rate = 74%).
Characteristics of Participants
Of the 621 respondents, 36% (n = 224) were aged 20 to 29
years, 27% (n = 167) were 30 to 39 years, 25% (n = 157)
were 40 to 49 years, and 12% (n = 73) were 50 to 59 years.
Of the 611 who reported their marital status, 60%
(n = 366) were married or cohabiting. Of the 618 who
reported their ethnic group, 96% (n = 596) classed them-
selves as white. One quarter (156/618) had a degree from
college or university. Just under one third (195/620) cur-
rently used the oral contraceptive pill. Approximately
two-thirds (416/621) had ever been pregnant, and 58%
(354/621) had children.
Of all the women, 66% (n = 409) had a negative
result in the surveillance cytology test, 24% had a low-
grade result (mild dyskaryosis, 37; BNA, 115), and 10%
had an ‘‘other’’ result (moderate dyskaryosis, 20; severe
dyskaryosis, 6; ?glandular, 1; inadequate, 33).
Prevalence of Cytologic Surveillance-Related Distress
Six weeks after the surveillance cytology test, 39% (244/
621) of respondents scored in the range for cytologic
surveillance-related distress. Of all the women, 24% had
mild distress (IES score = 9Y25; n = 151), 13% had
moderate distress (IES score = 26Y43; n = 79), and 2%
had severe distress (IES score Q44; n = 14). The mean IES
score was 10.3 (SD = 12.81), but the distribution of
scores across all women was highly skewed; the median
was 5 (interquartile range = 0Y17).







There was no significant difference in the prevalence
of distress according to the time between the initial and
follow-up cytology tests (e6 mo, 40%; 7Y9 mo, 39%;
10Y12 mo, 46%; Q13 mo, 33%). In addition, the prev-
alence of distress did not vary significantly according to
whether women had responded to the initial question-
naire mailing or the first or second reminder.
Predictors of Cytologic Surveillance-Related Distress
In multivariate models, compared to women with a neg-
ative surveillance cytology test result, those with a low-
grade result had a modest, nonsignificant, increased risk
of distress of any severity, and those with an ‘‘other’’ result
had a more than 2-fold increased risk (see Table 1). These
odds ratios translated into adjusted prevalence of distress
of 36.4% (95% confidence interval [CI] = 31.1%Y41.7%),
42.0% (95% CI = 33.7%Y50.8%), and 55.1% (95%
CI = 40.3%Y69.0%) for those with negative, low-grade,
and ‘‘other’’ results, respectively (see Figure 1). Among the
group with ‘‘other’’ surveillance cytology results, there
was little difference in the prevalence of distress among
those with an inadequate result (58%) and those with a
high-grade result (52%). Women with moderate or se-
vere surveillance-related distress were distributed across
all 3 surveillance test result groups, although the preva-
lence was lower among those with negative cytology
(13%) compared to those with low-grade (18%) and
‘‘other’’ cytology (22%).
In addition to the surveillance test result, the following
variables were significantly associated with surveillance-
related distress in the multivariate analyses: HADS anxiety
score at recruitment, reported pain after the surveillance
test, and reproductive history (see Table 1). There was an
almost 3-fold increased risk of distress among women
who scored 11 or higher on the HADS anxiety subscale
(probable cases) compared to those who scored less than
8 (noncases). Women who reported pain had a 2-fold
increased risk of distress compared to those who did not.
Women who had never been pregnant had a 40% lower
risk of surveillance-related distress compared to women
who had children. None of the other variables tested in
the first stage of model fitting was significantly associ-
ated with risk of distress.
When the individual components of the POSM were
considered, risk of distress was significantly increased
among those who had reported, after their recruitment
Table 1. Characteristics Significantly Associateda With Cytologic Surveillance-Related DistressVMultivariate
Odds Ratios (OR), Adjusted Prevalence, and 95% Confidence Intervals (CI)
Characteristic Multivariateb OR (95% CI) Adjusted prevalenceb (95% CI)
Surveillance cytology test resultc Normal 1 (reference) 36.3% (31.4%Y41.7%)
Low-grade 1.27 (0.83Y1.92) 42.0% (33.7%Y50.8%)
Other 2.15 (1.13Y4.06) 55.1% (40.3%Y69.0%)
Anxiety after recruitment BNA cytology testd Noncase 1 (reference) 33.2% (28.2%Y38.7%)
Possible case 1.29 (0.82Y2.03) 39.1% (30.4%Y48.6%)
Probable case 2.72 (1.73Y4.26) 57.5% (48.1%Y66.4%)
Pain after the surveillance cytology test No 1 (reference) 36.9% (32.5%Y41.6%)
Yes 1.98 (1.22Y3.21) 53.6% (42.6%Y64.3%)
Reproductive history Pregnant with children 1 (reference) 43.6% (38.0%Y49.4%)
Pregnant Y no children 0.88 (0.49Y1.58) 40.4% (28.3%Y53.8%)
Never pregnant 0.61 (0.40Y0.91) 31.9% (25.2%Y39.4%)
a In the multivariate model.
b Mutually adjusted for surveillance cytology test result, anxiety after recruitment BNA cytology test, pain after the surveillance cytology test and reproductive history.
c Low-grade includes BNA and mild dyskaryosis; other includes moderate and severe dyskaryosis, inadequate, and ?glandular.
d Assessed using the HADS at recruitment; on average, 8 weeks after receipt of BNA cytology test result.
BNA, borderline nuclear abnormality; HADS, Hospital Anxiety and Depression Scale.
Figure 1. Adjusted prevalence of distress,a by surveillance cytology
test result.b a Adjusted for anxiety after BNA recruitment cytology
test, pain after the surveillance cytology test, and reproductive his-
tory. b Low-grade result includes BNA and mild dyskaryosis; ‘‘other
result’’ includes inadequate, moderate or severe dyskaryosis, and
?glandular.







cytology test, that they were worried about their general
health, their next cytology test being abnormal, having
cervical cancer, and having sex (see Table 2). Women who
were not satisfied with the support they had received
from other people were also at a significantly increased
risk of distress.
DISCUSSION
Prevalence of Cytologic Surveillance-Related Distress
An important finding of this study was the high prevalence
of cytologic surveillance-related distress among women
with a single BNA (broadly equivalent to ASC-US) cytol-
ogy result managed by a repeat cytology test at 6 months
(39% overall). Although we did not assess distress in these
women after the initial abnormal cytology test, which was
performed within routine call and recall, we have previ-
ously shown that the prevalence of significant anxiety after
that initial cytology test was high [27]. The current study
suggests that that the adverse psychologic effects pro-
voked by the initial test persist over 6 months (and per-
haps longer) for many women. Although in most women
the level of distress would have been considered mild, 2%
overall scored in the range of severe distress and 13% in
the range of moderate distress. Considering the number
of women who have an ASC-US (or equivalent) routine
cytology test each year, our results suggest that follow-up
by cytologic surveillance imposes a significant psycho-
logic burden on women. However, this burden is not
limited to follow-up by repeat cytologic testing. One of
the main management alternativesVcolposcopyVis also
associated with a significant psychologic impact [28Y30].
Interestingly, the prevalence of distress in the current
study was higher than that found among women who had a
low-grade cytology test followed by a normal colposcopy
examination (21%) and was almost as high as among
women who had a low-grade cytology test followed by a
colposcopy in which an abnormal transformation zone
was found (42%) [31].
A lack of data makes it difficult to assess how the level
of distress associated with the management of a low-grade
cytology test compares to other medical procedures. The
average IES score among women in this study (mean =
10.3) was higher than means reported from (i) an as-
sessment made 2 months after lung cancer screening by
computed tomography (CT) among smokers (overall
mean = 3.6; normal CT result, mean = 2.4; indetermi-
nate CT result, mean = 8.3) [32] and (ii) an assessment
conducted 1 week after endoscopy among people with
Barrett’s esophagus (mean = 3.5) [33]. It was lower than
mean scores among women at high breast cancer risk,
some of whom had BRCA1/2 mutations, about to un-
dergo MRI surveillance (mean = 14.5) [34]; and a high-
risk group about to undergo genetic testing for hereditary
nonpolyposis colorectal cancer (mean = 14.7) [35].
The prevalence of distress was highest among the
group of women whose surveillance test result fell into
the ‘‘other’’ category (high-grade [equivalent to high-grade
squamous intraepithelial lesion], inadequate [called un-
satisfactory in some jurisdictions], or glandular). Women
with a high-grade result were informed that they would
be referred for colposcopy and it seems entirely plau-
sible that the result and/or the referral into hospital services
might well lead to higher distress. Those with inadequate
tests were recommended to have another test in three
months and this more rapid recall than woman may have
expected might have served to increase distress. In addi-
tion, women may be uncertain about what the label ‘‘in-
adequate’’ means and distress and anxiety are common
reactions to uncertainty [36]. Consistent with our find-
ings, another UK study also reported increased anxiety
and concerns at 4 weeks after receipt of results among
180 women whose cytology test result was classified as
inadequate [37]. In that study, the authors noted that
the levels of anxiety and concerns in women with an in-
adequate test result were similar to those among women
with a low-grade result, whereas in our study, the preva-
lence of surveillance-related distress among women with
an inadequate result was as high as for women with a
high-grade result. This may because of a difference in
Table 2. Other Psychosocial Factorsa Significantly
Associatedb With Cytologic Surveillance-Related
DistressVMultivariate Odds Ratios (OR), Adjusted





Worried about general health No 1 (reference) 27.6%
Yes 1.67 (0.94Y2.97) 39.0%
Worried my next smear will show No 1 (reference) 7.7%
changes to the cells Yes 7.80 (1.78Y35.95) 40.1%
Worried I may have cervical cancer No 1 (reference) 25.3%
Yes 2.04 (1.20Y3.46) 40.8%
Worried about having sex No 1 (reference) 32.0%
Yes 1.76 (1.13Y2.76) 45.4%
Satisfied with support from
other people
No 1 (reference) 59.4%
Yes 0.35 (0.16Y9.75) 33.9%
a From questions included in the POSM.
b In a model containing surveillance-cytology test result, anxiety after BNA recruitment
cytology test, pain after the surveillance cytology test, and reproductive history.
c Adjusted for surveillance cytology test result, anxiety following BNA recruitment cy-
tology, pain after the surveillance cytology test, and reproductive history.
BNA, borderline nuclear abnormality.







study settings: in the study by French et al. [37], women
had attended for routine screening, whereas in our study,
they were already on surveillance because of an abnormal
routine test. However, our finding should be interpreted
with a degree of caution because the number of women
who had an inadequate result was small.
It might have been expected a priori that women
whose surveillance test result was negative would be less
often distressed than other women. However, we ob-
served that the prevalence of distress was similar among
women with negative and low-grade surveillance test
results. This finding is broadly similar to that of Maissi
et al. [13] who, in a study of women with BNA and mildly
dyskaryotic routine cytology results, reported that the
result of the 6-month repeat test was not a predictor of
concern at that time, although in that study, many women
had not received their surveillance test result by the time
the psychologic assessment was conducted. A possible
explanation for our finding is that women with negative
and low-grade first surveillance test results are subse-
quently managed in the same way (i.e., by a second sur-
veillance test in another 6 months). By the time women in
our study completed the psychologic questionnaire, they
would have been informed of their test result and future
follow-up. This, in effect, means that women with a
negative test result received a mixed message Y that their
cytology result was ‘‘normal,’’ but management would
not be returning to ‘‘normal’’ (i.e., routine recall). As
well as being associated with a relatively high prevalence
of distress, this mixed message may have other conse-
quences. For example, we have previously shown that
women are more likely to default from subsequent sur-
veillance cytology tests if their first surveillance test
result is negative [38]. This means that it is possible that
a single intervention (e.g., additional information, pro-
vided when the first surveillance test is reported, including
emphasis on the importance of subsequent tests) could
help alleviate distress, provide reassurance, and decrease
default from follow-up.
The results of this study highlight the unintended con-
sequences of screening for participants. The sensitivity of
cytology means that a significant proportion of women
who attend for a routine screening test are labeled as
‘‘non-negative’’ and therefore need follow-up, although
their risk of developing cancer is low. We have shown
that follow-up, irrespective of whether it is by surveil-
lance or colposcopy [31], can have psychologic conse-
quences for a significant proportion of women. Triage
by HPV testing is now recommended in some jurisdictions
for women with low-grade cytology [39, 40]. Although
this strategy avoids the need for women to be managed by
repeat cytology tests, it is unlikely to eliminate the adverse
psychologic consequences associated with low-grade cy-
tology results. This is because women with low-grade
cytology who also test positive for HPV have increased
anxiety, distress, and concerns, whereas those who test
negative are not reassured [41] and, after 6 months,
women remain concerned about their cytology result
irrespective of their HPV result [13]. These issues point
to the importance, in designing screening protocols, of
taking into account sensitivity and specificity of both
the primary screening and triage tests: only by doing this
can an acceptable balance between the costs and the
benefits of screening be achieved.
Predictors of Cytologic Surveillance-Related Distress
It seems unsurprising that women who were anxious
after their recruitment cytology test were at increased
risk of distress after the repeat test. The association be-
tween having experienced pain after the repeat cytology
test and distress was also observed in our study of dis-
tress after colposcopy [31]. Because pain and distress
were assessed contemporaneously, it remains uncertain
whether pain is a predictor of distress or vice versa. How-
ever, the finding does raise the possibility that providing
women with information that quantifies the likelihood of
experiencing pain or discomfort after a cytology test,
and clarifies that this is not unusual, could ameliorate
subsequent distress.
The observed lower risk of distress in women who
have never been pregnant compared to those who have
children is intriguing. Although women who have never
been pregnant are younger, it seems unlikely that the re-
lationship would be due to age because age is not usually
an important predictor of IES scores [42]. One possible
explanation is that there may be differences between
women with and without children in what they consider
to be the potential implications of undergoing cytologic
surveillance. For example, women who have had abnormal
cytology tests and follow-up may worry about cervical
cancer [43, 44]; such concerns may be more common or
pronounced in women with children, translating into
raised levels of distress.
Identification of associations between specific worries
or concerns and distress might provide clues as to the
issues that underlie surveillance-related distress and help
inform the development of interventions to alleviate this.
Maissi et al. [13] found that, among women with low-
grade cytology managed by repeat cytology tests, those







who had a high perceived risk of developing cervical
cancer reported higher concerns at a 6-month follow-up
assessment. In our study, although perceived risk was not
associated with distress, women who reported after the
recruitment cytology test that they were worried that they
may have cervical cancer were 3 times more likely to be
distressed after the repeat test, than those who were not
worried. We support the suggestion of Maissi et al. [13]
that providing women on cytologic surveillance with in-
formation about their relatively low absolute chance of
developing cervical cancer might be effective in reducing
the psychologic burden.
The observed association between a lack of satisfaction
with support and distress has been reported also among
women managed by colposcopy [29, 31]. This suggests
another route by which service providers might try to
alleviate the adverse psychologic sequelae of follow-upV
by providing additional sources of support for women.
In the United Kingdom, where TOMBOLA took place,
there have been a range of developments since we con-
ducted the study, including the provision of screening
program and charity telephone help lines, and standard-
ized information available through the CSPs, and these
may have gone some way to providing this support. How-
ever, providing support that effectively meets the needs of
all women is likely to be challenging because women prob-
ably differ widely in their preferences for type, amount, and
timing of delivery of support, especially in jurisdictions in
which there is substantial ethnic and cultural diversity.
Strengths and Limitations
The major strengths of our study include the prospective
design and the fact that it was set within a pragmatic,
population-based trial that mimicked routine clinical
practice in the NHS CSPs. Although the questionnaire
response rate was high (74%), we cannot exclude the
possibility that nonresponders differed from responders
in their patterns of distress. Nonresponders differed from
responders in some (e.g., age, ethnic group) but not other
(e.g., employment status, educational level, reproductive
history) variables but, with the exception of reproductive
history, none of these variables were a significant pre-
dictor of distress. A higher proportion of nonresponders,
than responders, scored as probable cases on the HADS
anxiety subscale at recruitment. Because anxiety was pos-
itively related to subsequent distress, it is possible that
our study underestimates the prevalence of distress in the
population of women with a single BNA (or equivalent)
cytology result.
CONCLUSIONS
This study suggests that a substantial proportion of
women with a single BNA cytology test experience
surveillance-related psychologic distress after a follow-
up cytology test, even when the test result is negative.
Because many women require follow-up for abnormal
cervical cytology, this deserves recognition as an importantV
albeit unintendedVconsequence of cervical screening.
Strategies to alleviate this distress merit further attention.
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